drug acquisition
GSK Acquires Phase III-Ready Liver Drug Efimosfermin for Up to $2B to Enter MASH Arena
GSK; Boston Pharmaceuticals; efimosfermin alfa; Phase III; liver disease; MASH; SLD; drug acquisition; FGF21 analog
Revitalizing Cancer Therapy: UK Biotech Acquires Kyowa Kirin’s Former Drug for Epstein-Barr-Related Diseases
UK Biotech, Kyowa Kirin, cancer drug, Epstein-Barr virus, EBV-driven diseases, drug acquisition, therapy revival.
Shionogi Acquires Maze’s Pompe Disease Drug Following FTC’s Sanofi Deal Halt
Shionogi, Maze, Pompe disease, drug acquisition, FTC, Sanofi, $150 million